Desloratadine: A new, nonsedating, oral antihistamine

The Journal of allergy and clinical immunology

Volumn 107, Issue 4, 2001, Pages 751-762

  Geha, Raif S ^a   Meltzer, Eli O ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESLORATADINE; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL; ARTICLE; ASTHMA; DRUG INTERACTION; HAY FEVER; HUMAN; URTICARIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; DRUG INTERACTIONS; HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; RHINITIS, ALLERGIC, SEASONAL; URTICARIA;

EID: 0035319303     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.114239     Document Type: Article

References (41)

1. B. Lundback Epidemiology of rhinitis and asthma Clin Exp Allergy 28 Suppl 2 1998 3 10
2. WF. Schoenwetter Allergic rhinitis: epidemiology and natural history Allergy Asthma Proc 21 2000 1 6
3. MS Dykewicz S Fineman DP Skoner R Nicklas R Lee J Blessing-Moore Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology Ann Allergy Asthma Immunol 81 1998 478 518
4. P van Cauwenberge C Bachert G Passalacqua J Bousquet GW Canonica SR Durham Consensus statement on the treatment of allergic rhinitis Allergy 55 2000 116 134
5. RD Mann GL Pearce N Dunn S. Shakir Sedation with “non-sedating” antihistamines: four prescription-event monitoring studies in general practice BMJ 320 2000 1184 1186
6. MA Gonzalez KS. Estes Pharmacokinetic overview of oral second-generation H1 antihistamines Int J Clin Pharmacol Ther 36 1998 292 300
7. Astelin (azelastine hydrochloride) prescribing information Physicians’ desk reference 54th ed 2000 : Medical Economics Montvale (NJ) 3147 3148
8. LM. DuBuske Second-generation antihistamines: the risk of ventricular arrhythmias Clin Ther 21 1999 281 295
9. M Cvetkovic B Leake MF Fromm GR Wilkinson RB. Kim OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine Drug Metab Dispos 27 1999 866 871
10. Zyrtec (cetirizine) prescribing information Physicians’ desk reference 2000 : Medical Economics Montvale (NJ) 2404 2406
11. W Kreutner JA Hey J Anthes A Barnett S Young S. Tozzi Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist: 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects Arzneimittelforschung 50 2000 345 352
12. Affrime M, Gupta S, Banfield C, Rosenberg M, Cohen A. A pharmacokinetic profile of desloratadine in healthy adults including elderly subjects. Clin Pharmacokinet. In press.
13. 1 receptors Allergy 55 2000 277
14. Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy. In press.
15. + cells Clin Exp Allergy 27 1997 559 567
16. U Lippert S Kruger-Krasagakes A Moller U Kiessling BM. Czarnetzki Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist descarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines Exp Dermatol 4 1995 272 276
17. AM Vignola L Crampette M Mondain G Sauvere W Czarlewski J Bousquet Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells Allergy 50 1995 200 203
18. DK Agrawal A Berro RG. Townley Desloratadine attenuation of eosinophil chemotaxis, adhesion, and superoxide generation [abstract] Allergy 55 Suppl 63 2000 276
19. A Barnett LC Iorio W Kreutner S Tozzi HS Ahn A. Gulbenkian Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine Agents Actions 14 1984 590 597
20. W Kreutner JA Hey P Chiu A. Barnett Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist: 2nd communication: lack of central nervous system and cardiovascular effects Arzneimittelforschung 50 2000 441 448
21. Gupta S, Banfield C, Affrime M, Marco A, Cayen M, Herron J, et al. Desloratadine demonstrates dose proportionality in healthy adults. Clin Pharmacokinet. In press.
22. Gupta S, Banfield C, Affrime M, Padhi D, Marbury T, Glue P. Oral bioavailability of desloratadine is unaffected by food. Clin Pharmacokinet. In press.
23. Banfield C, Hunt T, Reyderman L, Statkevich P, Padhi D, Affrime M. Lack of interaction between desloratadine and erythromycin. Clin Pharmacokinet. In press.
24. Banfield C, Herron J, Keung A, Padhi D, Affrime M. Desloratadine has no electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet. In press.
25. DK. Yu The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions J Clin Pharmacol 39 2000 1203 1211
26. Y. Tanigawara Role of P-glycoprotein in drug disposition Ther Drug Monit 22 2000 137 140
27. JA. Silverman P-Glycoprotein RH Levy KE Thummel WF Trager PD Hansten M Eichelbaum Metabolic drug interactions. 2000 : Lippincott Williams & Wilkins Philadelphia 135 144
28. MN Cayen E Wang RP Clement WW. Johnson Effect of desloratadine on p-glycoprotein transport system (MDR1) [abstract] Allergy 55 Suppl 63 2000 282
29. A Johne J Brockmoller S Bauer A Maurer M Langheinrich I. Roots Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum) Clin Pharmacol Ther 66 1999 338 345
30. max and AUC of fexo-fenadine by 30% [abstract] Ann Allergy Asthma Immunol 86 2000 108
31. Affrime M, Banfield C, Gupta S, Rosenberg M, Cohen A, Boutros T, et al. Effect of race and sex on single- and multiple-dose pharmacokinetics of desloratadine. Clin Pharmacokinet. In press.
32. 1-receptor antagonist, in patients with seasonal allergic rhinitis. Assessment during the spring and fall allergy seasons Clin Drug Invest 21 2001 25 32
33. R Lorber LM Salmun MR. Danzig Desloratadine is effective at relieving nasal congestion, as demonstrated in three placebo-controlled trials in patients with seasonal allergic rhinitis [abstract] New Trends Allergy 2001 In press
34. GS. Rachelefsky National guidelines needed to manage rhinitis and prevent complications Ann Allergy Asthma Immunol 82 1999 296 305
35. DB Beckman LC. Grammar Pharmacotherapy to prevent the complications of allergic rhinitis Allergy Asthma Proc 20 1999 215 223
36. E Schenkel Desloratadine Study Group Desloratadine improved SAR symptoms in patients with mild-to-moderate asthma and SAR [abstract] Ann Allergy Asthma Immunol 86 2000 110
37. PH Ratner Desloratadine Study Group Desloratadine improved asthma symptoms and reduced bronchodilator use in 2 studies of patients with asthma and SAR [abstract] Ann Allergy Asthma Immunol 86 2000 109
38. J Ring R Hein A Gauger E Bronsky B Miller Desloratadine Study Group Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebocontrolled study Int J Dermatol 40 2001 1 5
39. MB Scharf GC Kay G Rikken MR Danzig H. Staudinger Desloratadine has no effect on wakefulness or psychomotor performance [abstract] Allergy 55 Suppl 63 2000 280
40. E Vuurman JG Ramaekers G Rikken F. de Halleux Desloratadine does not impair actual driving performance: a 3-way crossover comparison with diphenhydramine and placebo [abstract] Allergy 55 Suppl 63 2000 263 264
41. G Rikken MB Scharf MR Danzig H. Staudinger Desloratadine and alcohol co-administration: no increase in impairment of performance over that induced by alcohol alone [abstract] Allergy 55 Suppl 63 2000 277